1163253

Dapagliflozyna propanodiol

United States Pharmacopeia (USP) Reference Standard

• Synonim(y): Dapagliflozin propanediol monohydrate, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol (S)-propane-1,2-diol (1:1) monohydrate, (2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol propanediol monohydrate, BMS 512148 propanediol hydrate, BMS-512148 propanediol hydrate, Dapagliflozin (S)-propylene glycol monohydrate, Dapagliflozin propanediol hydrate
• Wzór empiryczny (zapis Hilla): C₂₁H₂₅ClO₆·C₃H₈O₂·H₂O
• Numer CAS: 960404-48-2
• Masa cząsteczkowa: 502.98
• UNSPSC Code: 41116107
• NACRES: NA.24
• MDL number: MFCD28167768

Właściwości

• grade: pharmaceutical primary standard
• agency: USP
• API family: dapagliflozin
• packaging: pkg of 100 mg
• manufacturer/tradename: USP
• application(s): pharmaceutical (small molecule)
• format: neat
• storage temp.: 2-8°C
• SMILES string: Clc1c(cc(cc1)[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)Cc2ccc(cc2)OCC.O[C@H](CO)C.O
• InChI: 1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1
• InChI key: GOADIQFWSVMMRJ-UPGAGZFNSA-N

Opis

General description

Find answers to frequently asked questions on USP products in USP FAQs.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets, have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Wzorzec referencyjny dapagliflozyny propanodiolu USP, przeznaczony do stosowania w określonych testach jakości i oznaczeniach, jak określono w kompendiach USP.

Biochem/physiol Actions

Dapagliflozin (BMS-512148) is an orally active, potent and selective renal sodium-dependent glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor (human/rat SGLT2 IC₅₀ = 1.1/3 nM vs. human/rat SGLT1 IC₅₀ = 1.39/0.6 μM; R-methyl-D-glucopyranoside (AMG) uptake assay with respective CHO transfectants). Dapagliflozin reduces blood glucose levels (by 55% in streptozotocin (STZ)-induced hyperglycemic rats 5 hrs post 0.1 mg/kg p.o.) by preventing the renal glucose reabsorption process and promoting glucose excretion in urine with good pharmacokinetic properties and oral availability (84% in rats and 83% in dogs, respectively, post 1 mg/kg and 6.6 mg/kg p.o.) in vivo.

Orally active, potent and selective renal sodium-dependent glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor with blood sugar-lowering efficacy in vivo.

Analysis Note

Produkty te są przeznaczone wyłącznie do testów i oznaczeń. Nie są one przeznaczone do podawania ludziom lub zwierzętom i nie mogą być stosowane do diagnozowania, leczenia lub wyleczenia jakichkolwiek chorób.

Other Notes

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 13 - Non Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable